Oppenheimer Sticks to Its Buy Rating for Chemed (CHE)

By Ryan Adsit

In a report released yesterday, Michael Wiederhorn from Oppenheimer maintained a Buy rating on Chemed (CHEResearch Report), with a price target of $535.00. The company’s shares closed last Monday at $491.58, close to its 52-week high of $494.76.

According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 17.4% and a 71.9% success rate. Wiederhorn covers the Services sector, focusing on stocks such as The Ensign Group, Addus Homecare, and Tivity Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Chemed with a $525.00 average price target.

See today’s analyst top recommended stocks >>

Based on Chemed’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $58.95 million. In comparison, last year the company had a net profit of $54.33 million.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CHE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.